EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2011

Conditions
Chronic Obstructive PulmonaryIdiopathic Pulmonary FibrosisCystic FibrosisBronchiectasisPulmonary Vascular Disease
Interventions
BIOLOGICAL

Placebo

placebo infusion, single

BIOLOGICAL

EZ-2053

single IV infusion, 9 mg/kg

BIOLOGICAL

EZ-2053 5mg/kg

single IV infusion, 5mg/kg

Trial Locations (19)

19104

University of Pennsylvania Medical Center, Philadelphia

19140

Temple University Hospital, Philadelphia

30322

Emory University School of Medicine, Atlanta

32224

Mayo Clinic, Jacksonville

37232

Vanderbilt University, Nashville

40536

University of Kentucky Medical Center, Lexington

44195

Cleveland Clinic, Cleveland

52242

University of Iowa Hospital & Clinics, Iowa City

63110

Barnes-Jewish Hospital, St Louis

73112

INTEGRIS Baptist Medical Center, Oklahoma City

77030

Baylor College of Medicine, Houston

78229

University of Texas Health Sciences Center, San Antonio

90048

Cedars-Sinai Medical Center, Los Angeles

94143

University of California, San Francisco, San Francisco

94305

Stanford University, Stanford

Unknown

The Alfred Hospital, Melbourne

Medical University of Vienna, Vienna

University of Alberta, Edmonton, Alberta

Toronto General Hospital, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Neovii Biotech

INDUSTRY